Singapore markets closed

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.68-0.51 (-2.53%)
As of 02:51PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
301,772
270,259
220,180
38,544
0
Cost of revenue
49,467
33,407
22,895
9,100
0
Gross profit
252,305
236,852
197,285
29,444
0
Operating expenses
Research development
87,259
76,097
65,490
99,297
112,042
Selling general and administrative
139,064
129,427
97,951
85,948
45,321
Total operating expenses
282,847
262,048
187,512
186,080
157,363
Operating income or loss
-30,542
-25,196
9,773
-156,636
-157,363
Total other income/expenses net
8,978
8,544
1,253
97
-
Income before tax
-21,564
-16,652
11,026
-156,539
-156,229
Income tax expense
-30,214
-30,736
-172,337
1,385
5,152
Income from continuing operations
8,650
14,084
183,363
-157,924
-161,381
Net income
8,650
14,084
183,363
-157,924
-161,381
Net income available to common shareholders
8,650
14,084
183,363
-157,924
-161,381
Basic EPS
-0.10
0.20
2.64
-2.30
-2.61
Diluted EPS
-0.11
0.20
2.60
-2.30
-2.61
Basic average shares
69,868
70,059
69,382
68,577
61,843
Diluted average shares
70,172
71,923
70,421
68,577
61,843